Could Investing in Moderna's Stock Double Your Money?

Moderna's stock has surged over 650% in 2026 driven by excitement around its cancer vaccine intismeran, developed with Merck. While the vaccine shows promising clinical trial results for melanoma and is being evaluated for other cancers, it remains unapproved. Despite this year's gains, the stock is still down 36% over five years. For the stock to double to a $180 billion valuation, Moderna would need strong revenue generation beyond expectations, making it a high-risk investment.